Bone Therapeutics may have escaped the graveyard thanks to a buyout by Medsenic last year, but the merged company continues to be haunted by clinical difficulties.
Belgian biotech Bone Therapeutics is no more as the inflammation and cell therapy company transforms into BioSenic.
Mont-Saint-Guibert, Belgium, October 25, 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces the closing of its acquisition of a majority participation in Medsenic, a privately held, clinical stage biotech company incorporated in France and specialized in the development of optimized formulations of arsenic Trioxide (ATO) and their applications in serious inflammatory/autoimmune conditions and other potential new indications in related fields.
Mont-Saint-Guibert, Belgium, 21 October 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces its business update for the third quarter, ended 30 September 2022.
Mont-Saint-Guibert, Belgium, 11 October 2022, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that it has received a transparency notification from S.F.P.I (Société Fédérale de Participation et d’Investissement)/F.P.I.M (Federale Participatien en Investeringsmaatschappij) dated 04 October 2022. The transparency notification indicates the shareholdings held by S.F.P.I/F.P.I.M have passively crossed below the threshold of 5%.
Mont-Saint-Guibert, Belgium, 7 October 2022, 8.15am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it will regain worldwide rights to its allogeneic, off-the-shelf, bone cell therapy platform ALLOB further to the unilateral termination notice received from Shenzhen Pregene Biopharma Co., Ltd. (“Pregene”).
Mont-Saint-Guibert, Belgium, 06 October 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the extraordinary general meeting to be held on Monday 24 October 2022 as from 03:00 pm CEST, at Avenue Lloyd George 11, 1000 Brussels, Belgium.
Mont-Saint-Guibert, Belgium, 31 August 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares following the conversion of convertible bonds (CBs) issued on 9 June 2022. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.
Mont-Saint-Guibert, Belgium, 26 August 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the extraordinary general meeting to be held on Monday 26 September 2022 as from 05:00 pm CEST, at Avenue Lloyd George 11, 1000 Brussels, Belgium.
A complex fracturing at Bone brings orthopedic biotechs in reverse merger deal